Loading...
Loading...
ENTA| Name | Value |
|---|---|
| Revenues | 17.8M |
| Cost of Revenue | 0.5M |
| Gross Profit | 17.3M |
| Operating Expense | 57.2M |
| Operating I/L | -39.5M |
| Other Income/Expense | 1.8M |
| Interest Income | 1.8M |
| Pretax | -37.6M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -37.7M |
Enanta Pharmaceuticals, Inc. is a biotechnology company specializing in the discovery and development of small molecule drugs for viral infections and liver diseases. Their research and development efforts target respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
